Developing Correlates of Protection for Vaccines Is Needed More than Ever-Influenza, COVID-19 and RSV Infection
- PMID: 39599786
- PMCID: PMC11598905
- DOI: 10.3390/v16111671
Developing Correlates of Protection for Vaccines Is Needed More than Ever-Influenza, COVID-19 and RSV Infection
Abstract
One of the greatest success stories of modern medicine is the prevention of infectious diseases by vaccination, most notably against smallpox and poliomyelitis. However, recent events, such as the 2009-2010 swine flu and the 2020 COVID-19 pandemics, as well as the continued emergence of highly pathogenic avian influenza viruses highlighted the fact that we still need to develop new vaccines, and perhaps we should be proactive, rather than reacting to epidemics and pandemics. However, the development of tools for evaluating novel vaccines has not been able to keep up with the rate of vaccine production. Humoral and cellular immune responses to vaccination have both been suggested to be important in preventing infections or ameliorating their consequences, although there is uncertainty regarding their exact roles and importance. This, together with the rapid development of new vaccines, means that the need for developing immunogenicity parameters, and even more importantly, reliable correlates of protection, is more important than ever.
Keywords: COVID-19; Influenza; RSV; antibody; immunity.
Conflict of interest statement
The authors declare no conflicts of interest.
Similar articles
-
Safety and immunogenicity of mRNA-1345 RSV vaccine coadministered with an influenza or COVID-19 vaccine in adults aged 50 years or older: an observer-blinded, placebo-controlled, randomised, phase 3 trial.Lancet Infect Dis. 2025 Apr;25(4):411-423. doi: 10.1016/S1473-3099(24)00589-9. Epub 2024 Nov 25. Lancet Infect Dis. 2025. PMID: 39608389 Clinical Trial.
-
A decavalent composite mRNA vaccine against both influenza and COVID-19.mBio. 2024 Sep 11;15(9):e0066824. doi: 10.1128/mbio.00668-24. Epub 2024 Aug 6. mBio. 2024. PMID: 39105586 Free PMC article.
-
Co-administration of seasonal quadrivalent influenza and COVID-19 vaccines leads to enhanced immune responses to influenza virus and reduced immune responses to SARS-CoV-2 in naive mice.Vaccine. 2025 Mar 19;50:126825. doi: 10.1016/j.vaccine.2025.126825. Epub 2025 Feb 7. Vaccine. 2025. PMID: 39921982
-
Towards broad-spectrum protection: the development and challenges of combined respiratory virus vaccines.Front Cell Infect Microbiol. 2024 Jun 5;14:1412478. doi: 10.3389/fcimb.2024.1412478. eCollection 2024. Front Cell Infect Microbiol. 2024. PMID: 38903942 Free PMC article. Review.
-
Influenza Virus and SARS-CoV-2 Vaccines.J Immunol. 2021 Jun 1;206(11):2509-2520. doi: 10.4049/jimmunol.2001287. Epub 2021 May 21. J Immunol. 2021. PMID: 34021048 Free PMC article. Review.
References
-
- [(accessed on 14 March 2024)]; Available online: https://www.fda.gov/news-events/press-announcements/fda-approves-first-v....
-
- Fazekas G., Martosne-Mendi R., Jankovics I., Szilvasy I., Vajo Z. Cross-reactive immunity to clade 2 strains of influenza virus A subtype H5N1 induced in adults and elderly patients by Fluval, a prototype pandemic influenza virus vaccine derived by reverse genetics, formulated with a phosphate adjuvant, and directed to clade 1 strains. Clin. Vaccine Immunol. 2009;16:437–443. - PMC - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical